Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

 

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

will cover in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge MA

 In Attendance, streaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

 

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

The MassBio Annual Meeting focuses on the most critical challenges facing the Massachusetts life sciences industry. The meeting program is designed by a steering committee of industry leaders and the agenda encompasses keynote presentations, panel discussions, interactive working sessions and extensive networking opportunities.

The MassBio Annual Meeting also includes the Innovative Leadership Award Luncheon, which honors an industry leader for his or her contribution to moving the life sciences industry forward.

AGENDA

 

 

Speakers

Plenary Sessions 

Price & Value 

• Katrine Bosley, CEO, Editas
• Jeff Elton, Managing Director, Global Life Sciences Management Consulting, Predictive Health Intelligence, Accenture (Moderator)
• John Glasspool, Executive Vice President and Head of Corporate Strategy and Customer Operations, Baxalta
• Peter Neumann, Director of the Center for the Evaluation of Value and Risk in Health, Tufts University

The 2016 National Landscape

• Jeanne Blake, Medical Television Journalist/News Anchor, Author, and Founder of Blake Works (Moderator)
• Ted Buckley, Senior Director, US Government Relations and Public Policy, Shire
• Amir Nashat, Managing Partner, Polaris
• Paris Panayiotopoulos, CEO, ARIAD

Advanced Manufacturing 

• John Aunins, Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer, Seres

Innovative Pricing Pricing Models: The Future is Now

• Laurie Bartlett Keating, Senior Vice President, Counsel, Alnylam
• Sue Hager, Vice President, Corporate Communications and Government Affairs, Foundation Medicine
• Steven Hass, Vice President for Patient Outcomes and Medical Economics, Sanofi Genzyme
• Roger Longman, CEO, Real Endpoint
• Peter Pitts, President and Co-Founder, CPMI (Moderator)

The Future of Finance & Capital Markets

• Francois Maisonrouge, Senior Managing Director, Evercore (Moderator)
• Roger Pomeranz, President, CEO and Chairman, Seres
• Rajeev Shah, Managing Director & Portfolio Manager, RA Capital

An Evolving Paradigm of Drug Discovery – Externalization, Virtualization, De-virtualization, Contract Research & Strategic Partnerships

• Ryan Brady, Vice President, Business Development, Evotec (Moderator)
• Brian Bronk, Principal, Sunrise Ventures, Sanofi Global R&D
• Arpita Maiti, Director, External R&D Innovation, Inflammation & Immunology, Pfizer
• Jeff Nye, Vice President, Neuroscience Innovation, Johnson & Johnson
• John Tomayko, CMO, Spero Therapeutics
• Samantha Truex, Chief Business Officer, Padlock Therapeutics

Digital Healthcare

• Dana Ball, CEO, Unitio/T1D
• Brian Dolan, Editor-in-Chief, MobiHealth News (Moderator)
• Naomi Fried, Vice President, Medical Information, Innovation and External Partnerships, Biogen
• Joe Kvedar, Vice President, Connected Health, Partners
• Laurance Stuntz, Director, MA E-Health Institute, MeHI/MassTech

Technology in Clinical Trials

• Yamo Deniz, Head of Rare Disease Medical Affairs, Sanofi Genzyme
• Hannes Smarason, Co-Founder & COO, WuXi NEXTCODE

The Microbiome 

• Jose-Carlos Gutierrez-Ramos, CEO, Synlogic

Immunotherapy in Combination

• Donnie McGrath, Vice President, Bristol Myers-Squibb
• John Orloff, Executive Vice President, Head of Research & Development and Chief Scientific Officer, Baxalta
• Helen Sabzevari, CSO & Co-Founder, Compass Therapeutics

Biosimilars 

• Sige Gutman, Chair, Life Sciences Patent Practice, Proskauer Rose (Moderator)
• Jim Roach, CMO, Momenta
• Alex Waldron, Vice President of Global Commercial Operations, Epirus Biopharmaceuticals

Science in Space

• Dr. George Church, Professor of Genetics, Harvard Medical School & Director, PersonalGenomes.org
• Kris Kimel, Co-Founder & Chairman of the Board, Space Tango
• Mike Roberts, Deputy Chief Scientist, Center for the Advancement of Science in Space
• Dr. Ting Wu, Professor of Genetics, Harvard Medical School, Director, Consortium for Space Genetics and Director, Personal Genetics Education (pgEd.org) Project (Moderator)

 

 

Just Announced!

Tony Coles to give closing keynote at Annual Meeting!

Dr. Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS).

Dr. Coles also serves as chairman and chief executive officer of TRATE Enterprises, LLC, a privately held company.

Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol-Myers Squibb Company. Additionally, from 1992 until 1996, Dr. Coles held a number of positions of increasing responsibility at Merck & Co., Inc.

Educated at Johns Hopkins University, he earned an M.D. from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.

Dr. Coles currently serves on the board of CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases  He also serves as a member of the board of directors of McKesson Corporation (NYSE: MCK), is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. In March 2015, Dr. Coles was named to the National Institutes of Health (NIH) working group tasked with charting the course for President Obama’s Precision Medicine Initiative, now part of the PMI Cohort Program Advisory Panel. Dr. Coles also serves as a member of the council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; and a member of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher.

Governor Charlie Baker to make opening remarks at the Annual Meeting!

Since taking office in January, 2015, Governor Charlie Baker has been making Massachusetts a great place to live, work, start a business and raise a family while delivering a customer service oriented state government that is as thrifty, creative and hard working as the people of Massachusetts.Governor Baker called on an expert, bipartisan team of Republicans, Democrats and Independents to lead his cabinet.

Together, they are fulfilling his commitment to building stronger and safer communities for our children and families; keeping our roads and bridges safe and reliable; protecting our natural resources; and ensuring our schools and students are successful and safe.

From resolve in the face of unprecedented snow and freezing temperatures, to working to fix the MBTA, the Department of Children and Families, the Health Connector and Registry of Motor Vehicles, to balancing budgets despite billions in deficits all without raising taxes – the Baker Political Administration is making state government truly work for the people of Massachusetts.

SOURCE

https://www.massbio.org/events/2016-massbio-annual-meeting-1120